RxDoctor Payments Data

Robert Pintauro

Adult Health · Bronx, NYNPI 1821539560

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.4% of the total across 701 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $5,631 and has fallen 78.9% since, to $1,187 in 2025. Among adult health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,531in general payments, 2019–2025

Across 701 payments — averaging $29.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$3K
  • AstraZeneca$2K
  • Amgen$1K
  • GSK$1K
  • Lilly USA, LLC$1K
  • plus $9K from 40 others

What the payments were for

  • Food & beverage$20,19598%
  • Education$3362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,531 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$134,740
MounjaroTirzepatide60$64,906
FarxigaDapagliflozin Propanediol61$61,130
JardianceEmpagliflozin48$50,115
EliquisApixaban48$44,569
TrulicityDulaglutide42$39,697
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$36,596
Diclofenac Sodium54$34,593
JanuviaSitagliptin Phosphate25$21,184
RexultiBrexpiprazole12$17,326
XareltoRivaroxaban27$16,215
MyrbetriqMirabegron18$14,612
Repatha SureclickEvolocumab25$13,077
VascepaIcosapent Ethyl16$12,162
ZenpepLipase/Protease/Amylase22$8,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$3,166$134,740107 claims
Lilly USA, LLCMounjaro, Trulicity$1,035$104,603102 claims
AstraZenecaFarxiga$1,856$61,13061 claims
Boehringer IngelheimJardiance$627$50,11548 claims
PfizerEliquis$427$44,56948 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,077$43,04060 claims
MerckJanuvia$202$21,18425 claims
Otsuka America Pharmaceutical, Inc.Rexulti$826$17,32612 claims
Johnson & JohnsonXarelto$25$16,21527 claims
Astellas Pharma US IncMyrbetriq$347$14,61218 claims
AbbVieSynthroid$2,643$1,49814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.

Other adult health in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →